JAMES SLIGH, MD
Dermatology at Campbell Ave, Tucson, AZ

License number
Arizona 40985
Category
Osteopathic Medicine
Type
Dermatology
Address
Address
1515 N Campbell Ave, Tucson, AZ 85724
Phone
(520) 626-6024

Personal information

See more information about JAMES SLIGH at radaris.com
Name
Address
Phone
James Sligh, age 59
5927 N Paseo Ventoso, Tucson, AZ 85750
(520) 395-2390
James Sligh
Marana, AZ
(520) 395-2390

Professional information

See more information about JAMES SLIGH at trustoria.com
James Edwin Sligh Photo 1
James Edwin Sligh, Tucson AZ

James Edwin Sligh, Tucson AZ

Specialties:
Dermatology, Dermatopathology, Dermatopathology
Work:
Southern Arizona Va Health Care System
3601 S 6Th Ave, Tucson, AZ 85723
Education:
Baylor College of Medicine (1995)


James Sligh Photo 2
Dr. James Sligh, Tucson AZ - MD (Doctor of Medicine)

Dr. James Sligh, Tucson AZ - MD (Doctor of Medicine)

Specialties:
Dermatology
Address:
Arizona Cancer Center
3838 N Campbell Ave, Tucson 85719
(520) 694-2873 (Phone)
Certifications:
Dermatology, 2008
Awards:
Healthgrades Honor Roll
Languages:
English
Hospitals:
Arizona Cancer Center
3838 N Campbell Ave, Tucson 85719
The University of Arizona Medical Center
1501 North Campbell Ave, Tucson 85724
Education:
Medical School
Baylor University
Graduated: 1995
Baylor College Of Med
Emory University School Of Med


James Sligh Photo 3
Ant2 Conditional Knockout Mouse And Methods

Ant2 Conditional Knockout Mouse And Methods

US Patent:
2008026, Oct 30, 2008
Filed:
Oct 12, 2007
Appl. No.:
11/871956
Inventors:
Douglas C. Wallace - Irvine CA, US
Grant MacGregor - Irvine CA, US
Katrina Waymire - Irvine CA, US
Shawn E. Levy - Hendersonville TN, US
James E. Sligh - Tucson AZ, US
Jason E. Kokoszka - Fairhope AL, US
Assignee:
Emory University - Atlanta GA
International Classification:
C12Q 1/68, A01K 67/027, C12N 5/18, C12Q 1/02, G01N 33/68
US Classification:
435 6, 800 18, 435354, 4353171, 435 29, 436 86
Abstract:
Described are methods for inactivating adenine nucleotide transporter proteins in specific tissues of a transgenic nonhuman animal using a conditional knockin/knockout technology such as the Cre-LoxP, Flip-FLP recombinase, or Tet-on/off technologies. Specifically, the Ant2 gene is functionally inactivated in a mouse in liver, with or without the concurrent inactivation of the Ant1 gene. The result is an animal in which the Ant2 gene and accompanying ANT 2 protein is absent in one or more tissues, either in the presence or absence of the Ant1 gene and accompanying protein. The resulting animals, cells, mitochondria, and subcelluar fractions such as the mitochondrial permeability transition pore can then be used to identify agents that affect animal and/or subcellular function via a direct or indirect interaction with the ANT2 protein and/or its Ant2 gene.